- Home
- PLBC vs EDIT Comparison
PLBC vs EDIT Comparison
Compare PLBC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- EDIT
- Stock Information
- Founded
- PLBC 1980
- EDIT 2013
- Country
- PLBC United States
- EDIT United States
- Employees
- PLBC N/A
- EDIT N/A
- Industry
- PLBC Finance Companies
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLBC Finance
- EDIT Health Care
- Exchange
- PLBC Nasdaq
- EDIT Nasdaq
- Market Cap
- PLBC 236.7M
- EDIT 248.2M
- IPO Year
- PLBC 2005
- EDIT 2016
- Fundamental
- Price
- PLBC $44.38
- EDIT $2.69
- Analyst Decision
- PLBC Buy
- EDIT Buy
- Analyst Count
- PLBC 4
- EDIT 12
- Target Price
- PLBC $57.00
- EDIT $5.40
- AVG Volume (30 Days)
- PLBC 12.3K
- EDIT 1.3M
- Earning Date
- PLBC 10-15-2025
- EDIT 11-03-2025
- Dividend Yield
- PLBC 2.70%
- EDIT N/A
- EPS Growth
- PLBC 1.22
- EDIT N/A
- EPS
- PLBC 4.86
- EDIT N/A
- Revenue
- PLBC $84,003,000.00
- EDIT $38,901,000.00
- Revenue This Year
- PLBC $22.16
- EDIT N/A
- Revenue Next Year
- PLBC $17.58
- EDIT N/A
- P/E Ratio
- PLBC $9.14
- EDIT N/A
- Revenue Growth
- PLBC 6.85
- EDIT N/A
- 52 Week Low
- PLBC $37.69
- EDIT $0.91
- 52 Week High
- PLBC $51.33
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- PLBC 56.57
- EDIT 51.07
- Support Level
- PLBC $42.52
- EDIT $2.56
- Resistance Level
- PLBC $46.59
- EDIT $2.84
- Average True Range (ATR)
- PLBC 0.98
- EDIT 0.17
- MACD
- PLBC 0.20
- EDIT 0.00
- Stochastic Oscillator
- PLBC 52.37
- EDIT 58.82
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.